Defibrillator Market Is Anticipated To Grow At A CAGR 6.8% From 2012 To 2020: Grand View Research, Inc.

The Global Defibrillator Market is expected to reach USD 15.75 billion by 2020, according to a new report by Grand View Research Inc. Increasing prevalence of cardiovascular diseases coupled with rising adoption rate of remote and regular patient monitoring is expected to boost the defibrillator market over the forecast period. The market is anticipated to grow at a CAGR 6.8% during the forecast period.

Rising work related stress and exposure to harmful chemicals such as carbon monoxide, lead, arsenic, and unhealthy lifestyle habits are vital causes triggering cardiac diseases. Lack of availability of prompt treatment in case of sudden cardiac arrest (SCA) is another important factor promoting the growth.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/defibrillators-market 

Further key findings from the study suggest:

• Strategic initiatives by healthcare federal bodies such as the distribution and widespread access of automated external defibrillators (AED) in public buildings and spaces further propels the expansion of the market. This initiative was begun after a study projected that over 700 people die per day due to unavailability of treatment for sudden cardiac arrest. 
• Implantable cardioverter defibrillator device is expected to report revenue of over 8 billion by 2020 due to enhancement in the technology and reduced number of sudden deaths. External defibrillators are expected to report a CAGR of 7.1% due to new software and smaller implant development. Ilesto DX, a product offered by Biotronik is first of its kind, allowing complete atrial diagnosis with a single defibrillator lead. Home care and public access market together are expected to register lucrative growth with revenue over 1.1 billion by 2020. Faster treatment availability and reduced hospital visits is the principal driver for the development. 
• North American region is anticipated to contribute over 35.0% of revenue in 2020, owing to rising geriatric population, favorable government initiatives pertaining to faster therapy availability, sophisticated healthcare infrastructure and increasing patient awareness levels coupled with relatively higher healthcare expenditures in the region. 
• Asia Pacific region is projected to reach over USD 3.5 billion by registering lucrative growth throughout the forecast period. The growth is attributed to the larger untapped opportunities, rising healthcare expenditure, augmenting disease prevalence rate, and supportive government initiatives and concession. 
• Major players of the industry include Boston Scientific Corporation, ZOLL Medical Corporation, St. Jude’s Medical, Medtronic, Biotronik, and Cardiac Science Corporation. St. Jude’s Medical offer the ShockGuard technology in their devices that facilitate in differentiation between true ventricular tachycardia and other lead noises thereby promoting higher safety of the patient. 

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the global defibrillator market on the basis of products, end-use and region:
Global Defibrillator Market Product Outlook (Market Revenue in USD Million, 2012 - 2020)
    • Implantable Cardioverter Defibrillator
            o Single Chamber Implantable Cardioverter Defibrillator
            o Dual Chamber Implantable Cardioverter Defibrillator
    • External Defibrillator
            o Manual External Defibrillator
            o Automated External Defibrillator
            o Wearable Cardioverter Defibrillators
Global Defibrillator End-use Outlook (Revenue, USD Million, 2012 - 2020)
    • Hospital
    • Pre Hospital
    • Public Access Market
    • Alternate Care Market
    • Home Health Care
Defibrillator Market Regional Outlook (Market Revenue in USD Million, 2012 - 2020)
    • North America
            o U.S.
            o Rest of North America
    • Europe
            o Germany
            o UK
            o Rest of Europe
    • Asia Pacific
            o Japan
            o China
            o India
            o Rest of Asia Pacific
    • Latin America
            o Brazil
            o Mexico
            o Rest of Latin America
    • Middle East and Africa
            o South Africa
            o Rest of Middle East and Africa

For press release of this report - http://www.grandviewresearch.com/press-release/global-defibrillators-market

Clinical Trial Management System Market Forecast To Reach USD 2.2 Billion By 2024: Grand View Research, Inc.

The global Clinical Trial Management System (CTMS) market is expected to reach USD 2.2 billion by 2024, according to a new report by Grand View Research, Inc.

Rising research activities and increasing complexity in data management for multiple verticals such as pharmaceutical and biotechnology are anticipated to present the clinical trial management system market with lucrative opportunities over the forecast period. These systems are capable for speeding up the research activity along with cost containment which is crucial for pharmaceutical companies that invest a lot on R&D innovation.

The present business scenario is witnessing rapid changes in the marketplace and consumer preferences are pushing the players to innovate and generate better performing products at a faster rate, in order to sustain the competition. Owing to the aforementioned reason, CTMS are designed in way that requires minimal documentation by clinical trial professionals avoids unnecessary & repeat testing and facilitates easy payment management. This at the end makes the whole process faster and reduces the time to market.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/clinical-trial-management-system-ctms-market

Further key findings from the study suggest:

• Enterprise based CTMS segment is expected to hold maximum shares and witness the fastest growth over the forecast period. Enterprise system dominated owing to their convenience and multiple user access. For instance, the enterprise CTMS currently being used in the University of Minnesota which offers implementation of a variety of functions via its core module.
• Cloud-based delivery mode is expected to witness the fastest growth and contribute over 15.0% share by 2024. Increasing popularity leading to higher adoption by end-users for cloud-based CTMS is the vital impact rendering driver.
• Pharmaceutical & biotechnology firms held about 40.0% share in 2025 and is expected to contribute highest revenue over the forecast period. Extensive pipeline and rising affinity towards collaborative research over the next decade is predicted to boost market growth.
• Asia Pacific is projected to drive the market growth and provide numerous opportunities to industry players. The efforts by government officials and research industry towards improving infrastructure, rising number of research studies and digitalization coupled with centralization of the management systems are promoting growth of CTMS market over the forecast period.
• The market is highly fragmented with numerous budding small scale companies. Few of the participants include; PARAXEL International Corporation, DATATRAK, Guger Technologies, Forte Research Systems Inc., MedNet Solutions, Bioclinica, Medidata Solutions Inc., and Oracle Corporation.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/healthcare-it

Grand View Research has segmented the global CTMS market on the basis of type, delivery mode, component, end-users and region.
By Type (USD Million), 2013 - 2024

·         Enterprise

·         Site

By Delivery Mode (USD Million), 2013 - 2024

·         Web-Based

·         Cloud-Based

·         On-Premise

By Component (USD Million), 2013 - 2024

·         Software

·         Service

By End-users (USD Million), 2013 - 2024

·         Pharmaceutical & Biotechnology Firms

·         Clinical Research Organizations (CROs)

·         Medical Device Firms

·         Others

By Region (USD Million), 2013 - 2024

·         North America

o    U.S.

o    Canada

·         Europe

o    UK

o    Germany

·         Asia Pacific

o    Japan

o    China

·         Latin America

o    Brazil

o    Mexico

·         MEA

o    South Africa

For press release of this report - http://www.grandviewresearch.com/press-release/global-clinical-trial-management-system-ctms-market

Anxiety Disorders And Depression Treatment Market Is Expected To Reach USD 18.3 Billion By 2025: Grand View Research, Inc.

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/anxiety-disorders-and-depression-treatment-market

Further key findings from the study suggest:

• Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment’s growth is expected to wane
• Patent expiration of branded medicines and introduction of generic biosimilars, which are cost effective, are responsible for the shrinking market of antidepressants
• On the other hand, introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, are predicted to fuel the demand for therapeutics in the coming years 
• Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
• Cognitive behavioral therapy held the majority share in 2015 and is expected to register substantial growth in the coming years owing to the shifting preference of healthcare professionals toward this segment
• Transcranial Magnetic Stimulation (TMS) is predicted to witness lucrative growth due to the introduction of technologically advanced devices such as MagVita TMS Therapy System by MagVenture in July 2015 and Brainsway Deep TMS in January 2013
• North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
• Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical
• The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the anxiety disorders and depression treatment market by product, indication, and region:
Anxiety Disorder and Depression Treatment Product Outlook (Revenue, USD Million, 2014 - 2025)

·         Antidepressant drugs

o    SSRIs

o    SNRIs

o    TCAs

o    MAOIs

o    Atypical Antipsychotics

o    Benzodiazepines

o    Anticonvulsants

o    Beta-Blockers

o    Others

·         Therapy & Devices

o    Fischer Wallace Stimulator

o    TMS

o    DBS

o    VNS

o    ECT

o    CBT

o    Others

Anxiety Disorder and Depression Treatment Indication Outlook (Revenue, USD Million, 2014 - 2025)

·         MDD

·         OCD

·         Phobias

·         Others

Anxiety Disorder and Depression Treatment Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    Japan

o    China

o    India

·         Latin America

o    Brazil

o    Mexico

·         The Middle East and Africa

o    South Africa

For press release of this report - http://www.grandviewresearch.com/press-release/global-anxiety-disorders-and-depression-treatment-market

Europe In Vitro Diagnostics Market To Represent USD 15.5 Billion Opportunity Globally By 2024: Grand View Research, Inc.

The Europe IVD market is expected to reach over USD 15.5 billion by 2024 according to a new report by Grand View Research, Inc. This expected increase in the demand is ascribed to the presence of novel and promising technologies in clinical laboratories, such as the introduction of Troponin T test by Roche Diagnostics in May, 2011.

Persistent research and development efforts made to introduce automation in laboratories that perform analytical testsare projected to propel the market growth over the forecast period. Clinical laboratory operations require automated analyzers to cope with the large test volumes,which enhance the overall operational workflow. It minimizes the need for dedicated operator training andnegates the risk of human errors. In addition, the rising demand for portable and handheld IVD devicesis one of the major factors pushing forward the growth of the market.

The increasing prevalence of chronic diseases, such as diabetes, cancers, and cardiac dysfunctions and the rising geriatric population coupled with the rising awareness towards early diagnosis in low-income countries, such as Bulgaria, Finland, Malta, and Estoniaare the potential drivers of the Europe IVD market.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/europe-in-vitro-diagnostics-ivd-market

Further key findings from the study suggest:

• In 2015, the reagents segment dominated the Europe IVD market due to its increasing number of applications in the companion diagnostics area and the introduction of disease specific kits, such as the XpertTB kit
• The IVD instruments market is anticipated to show lucrative growth due to the introduction of portable instruments, such as MinION Analyzer by Oxford Nanopore, and the availability of various platforms to performtarget sequence analysis, thereby driving the overall demand
• Germany is one of the largest segments in 2015 with a share of over 19% owing to the presence of a larger geriatric population base in this region and the amendment ofthe German lawfor the prevention of hospital-acquired infections
• UK is expected to be the fastest growing regionduring the forecast period.The rising demand for the point-of-care devices coupled with the government interventions to incorporate innovative, cost-effective solutions in the healthcare services are expected to drive the market growth during the forecast period.
• The hospital-based IVD testing segment held the largest share of over 45% in 2015. The highprocedure volumes in this segment, is one of the major reasons resulting inthehigh share and;hence, is anticipated to maintain its market position over the forecast period.
• The market players of the Europe IVD market include Alere, Inc., bioMerieux, Inc., Hologic, Inc. (Gen-Probe), Roche Diagnostics, Qiagen N.V., Bio-Rad Laboratories, Inc., Quidel Corporation, Abbott Laboratories, Inc., Becton, Dickinson (BD) and Company, Inc., and Siemens Healthcare GmbH
• The presence of major IVD market players in Europe accelerates the penetration of the IVD products throughout the European Union. For instance, in September 2014, Roche Diagnostics launched the CE approved Cobas 6800/8800 systems, which offers IVD-based viral load monitoring withenhanced flexibility and automation.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the Europe IVD market on the basis of product, technology, application, test location, and region:
Europe In-Vitro Diagnostics (IVD) Market, by Product (USD Million), 2013 - 2024

·         IVD Instruments

·         IVD Reagents

·         Services

·         Data Management

Europe In-Vitro Diagnostics (IVD) Market, by Technique (USD Million), 2013 - 2024

·         Immunochemistry

·         Microbiology

·         Molecular diagnostics

·         Hematology

·         Clinical Chemistry

·         Coagulation

·         Other Clinical Instruments

Europe In-Vitro Diagnostics (IVD) Market, by Application (USD Million), 2013 - 2024

·         Infectious Diseases

·         Diabetes

·         Oncology/Cancer

·         Cardiology

·         Nephrology

·         Autoimmune Diseases

·         Drug Testing

·         Others

Europe In-Vitro Diagnostics (IVD) Market, by End-use (USD Million), 2013 - 2024

·         Hospitals

·         Laboratory

·         Patient self-testing

·         Point-of-care testing

·         Academics

·         Others

Europe In-Vitro Diagnostics (IVD) Market, by Country (USD Million), 2013 - 2024

·         Germany

·         UK

·         France

·         Switzerland

·         Spain

·         Italy

·         Belgium

·         Austria

·         Netherlands

·         Sweden

For press release of this report - http://www.grandviewresearch.com/press-release/europe-in-vitro-diagnostics-ivd-market-analysis